# Align Technology, Inc. (ALGN)

> Source: Nexqual · https://nexqual.com/ALGN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Align Technology, Inc. (ALGN), nexqual.com/ALGN" · informational, not investment advice.

**Price:** USD 155.51 (+2.73% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 155.51 · day 151.44–155.94 · 52w 130.23–200.44 · market cap null · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $4.14B, net income $414M (10.0% margin), free cash flow $634M (SEC filings).
- 1 of 80 tracked superinvestors hold ALGN (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +14.3% vs S&P 500 +14.9%; 5Y -73.7% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 2.77, revenue estimate $1.00B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.95B | $3.73B | $3.86B | $4.00B | $4.03B | $4.14B |
| Gross profit | $2.94B | $2.63B | $2.71B | $2.80B | $2.71B | — |
| Operating income | $976M | $643M | $643M | $608M | $546M | $548M |
| Net income | $772M | $362M | $445M | $421M | $410M | $414M |
| EPS (diluted) | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 | — |
| Free cash flow | $771M | $277M | $608M | $623M | $491M | $634M |
| Gross margin | 74.3% | 70.5% | 70.1% | 70.0% | 67.2% | — |
| Operating margin | 24.7% | 17.2% | 16.7% | 15.2% | 13.5% | 13.2% |
| Net margin | 19.5% | 9.7% | 11.5% | 10.5% | 10.2% | 10.0% |
| Revenue growth | +59.9% | -5.5% | +3.4% | +3.5% | +0.9% | — |
| Cash + short-term investments | $1.17B | $1000M | $973M | $1.04B | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)

P/E at fiscal year-ends: Dec 2025 27.6x, Dec 2024 37.1x, Dec 2023 47.1x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ALGN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Ruane Cunniff | Ruane Cunniff LP | 3.07% | $198M | Reduced -2.9% |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Mizuho | Target lowered | Outperform | $220 → $200 |
| 2026-10-21 | Piper Sandler | Target lowered | Overweight | $235 → $205 |
| 2026-10-15 | Baird | Downgrade | Outperform → Neutral | $218 → $162 |
| 2026-10-14 | Leerink Partners | Target lowered | Outperform | $235 → $215 |
| 2026-10-09 | Stifel | Target lowered | Buy | $210 → $175 |
| 2026-10-05 | Evercore ISI Group | Downgrade | Outperform → In-Line | $220 → $155 |
| 2026-07-23 | UBS | Target raised | Neutral | $186 → $189 |
| 2026-07-09 | BMO Capital | Initiated | Outperform | $209 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +14.3% | -73.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +14.4% | -23.4% |
| Volatility (annualized) | 39.2% | 49.3% |
| Max drawdown | -29.2% (Feb 2026→Oct 2026) | -81.7% (Nov 2021→Oct 2025) |

## Peers (Medical Instruments & Supplies)
COO (The Cooper Companies, Inc.) USD 61.65 +4.54% · RGEN (Repligen Corporation) USD 178.71 -0.72% · AVTR (Avantor, Inc.) USD 17.15 -0.64% · BAX (Baxter International Inc.) USD 25.65 +3.85% · ATR (AptarGroup, Inc.) USD 128.1 +1.97% · SOLV (Solventum Corporation) USD 87.45 +0.90%

## More
Full page: https://nexqual.com/ALGN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.77 | $2.90 | -4.6% | $1.00B | 14 |
| Next quarter (ends 2026-12-31) | $3.17 | $3.29 | -3.8% | $1.05B | 14 |
| Current fiscal year (ends 2026-12-31) | $11.21 | $11.36 | -1.3% | $4.15B | 15 |
| Next fiscal year (ends 2027-12-31) | $12.40 | $12.38 | +0.2% | $4.29B | 16 |